Tags : Hypertension

Exelixis and Daiichi Report Launch of Minnebro (Esaxerenone) Tablets for

Shots: The approval of Minnebro (Esaxerenone) tablets (1.25/2.5/5 mg) is based on P-III ESAX-HTN study in patients with hypertension, with its regulatory approval submitted to MHLW in Feb’18 In Q2’19, Exelixis will receive $20M as milestone payment from Daiichi, as per their research collaboration for the development of therapies targeting mineralocorticoid receptor signed in 2006 […]Read More

Exelixis and Daiichi Sankyo’s Minnebro (Esaxerenone) Receives MHLW Marketing Approval

Shots: The approval is based on P-III ESAX-HTN study assessing esaxerenone vs eplerenone for 12wks. in patients with essential hypertension, 1EP as SBP / DBP In 2006, Exelixis and Daiichi Sankyo collaborated to develop and commercialize and Esaxerenone tablets. Exelixis will receive $20M milestone on sales and has received additional $20M as on regulatory milestones in […]Read More

Mylan Recalls 15 Batches of Valsartan Globally, for the Treatment

Shots: Mylan has recalled globally, 6 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, and 10mg/320mg strengths), 7 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg, and 320 mg strengths) and 2 lots of Valsartan and Hydrochlorothiazide Tablets, USP (320mg/25mg strength) , detected with traces of N-nitrosodiethylamine (NDEA) […]Read More